{"id":"https://openalex.org/W4404025516","doi":"https://doi.org/10.1158/1078-0432.27609917","title":"Supplementary Table S2 from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody\u2013Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non\u2013Small Cell Lung Carcinoma","display_name":"Supplementary Table S2 from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody\u2013Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non\u2013Small Cell Lung Carcinoma","publication_year":2024,"publication_date":"2024-11-04","ids":{"openalex":"https://openalex.org/W4404025516","doi":"https://doi.org/10.1158/1078-0432.27609917"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.27609917","doi":"https://doi.org/10.1158/1078-0432.27609917","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609917","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.27609917","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Ross Camidge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031420337","display_name":"Daniel Morgensztern","orcid":"https://orcid.org/0000-0003-4349-2028","observed_orcids":["https://orcid.org/0000-0003-4349-2028"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Morgensztern","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064382279","display_name":"Rebecca Suk Heist","orcid":"https://orcid.org/0000-0002-7397-2009","observed_orcids":["https://orcid.org/0000-0002-7397-2009"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca S. Heist","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015591858","display_name":"Minal A. Barve","orcid":"https://orcid.org/0009-0007-4259-7457","observed_orcids":["https://orcid.org/0009-0007-4259-7457"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minal Barve","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Everett Vokes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8645-8068","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036134937","display_name":"Jonathan Wade Goldman","orcid":"https://orcid.org/0000-0002-4925-8243","observed_orcids":["https://orcid.org/0000-0002-4925-8243"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan W. Goldman","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4925-8243","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8721-1609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Todd M. Bauer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005968330","display_name":"John H. Strickler","orcid":"https://orcid.org/0000-0001-7579-1175","observed_orcids":["https://orcid.org/0000-0001-7579-1175"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John H. Strickler","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7579-1175","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028436035","display_name":"Eric Angevin","orcid":"https://orcid.org/0000-0001-6249-7209","observed_orcids":["https://orcid.org/0000-0001-6249-7209"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Angevin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103552874","display_name":"Monica Motwani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Monica Motwani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011356640","display_name":"Apurvasena Parikh","orcid":"https://orcid.org/0000-0003-3711-8718","observed_orcids":["https://orcid.org/0000-0003-3711-8718"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Apurvasena Parikh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3711-8718","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079615978","display_name":"Zhaowen Sun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhaowen Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042122044","display_name":"Bruce Allen Bach","orcid":"https://orcid.org/0000-0003-3535-9518","observed_orcids":["https://orcid.org/0000-0003-3535-9518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce Allen Bach","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101407043","display_name":"Jun Wu","orcid":"https://orcid.org/0000-0002-6922-8762","observed_orcids":["https://orcid.org/0000-0002-6922-8762"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033776778","display_name":"Philip B. Komarnitsky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip B. Komarnitsky","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5077352149","display_name":"Karen L. Kelly","orcid":"https://orcid.org/0000-0002-2235-6636","observed_orcids":["https://orcid.org/0000-0002-2235-6636"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Kelly","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2235-6636","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/telisotuzumab-vedotin","display_name":"telisotuzumab vedotin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.8220000267028809},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9710000157356262},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8429999947547913},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/dose-interruption","display_name":"dose interruption","score":0.8539999723434448},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.9240000247955322},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.6610000133514404},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.8802508115768433},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7424950003623962},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.6845536231994629},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6070970892906189},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5202696919441223},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4882550537586212},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.44068247079849243},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41211211681365967},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3843690752983093},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3498595952987671},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.31107789278030396},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1944740116596222},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.1546042263507843},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.06513187289237976},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.27609917","doi":"https://doi.org/10.1158/1078-0432.27609917","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609917","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/27609917","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_S2_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609917","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.27609917","doi":"https://doi.org/10.1158/1078-0432.27609917","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609917","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4404025507","https://openalex.org/W3194878909","https://openalex.org/W4415519064","https://openalex.org/W2898202326","https://openalex.org/W4281670642","https://openalex.org/W2894761459","https://openalex.org/W4415940769","https://openalex.org/W7160525927","https://openalex.org/W4248096473","https://openalex.org/W3205823644"],"abstract_inverted_index":{"Supplementary":[0],"Table":[1],"S2":[2],"shows":[3],"time":[4],"course":[5],"of":[6],"peripheral":[7,20],"neuropathy":[8,21],"development":[9],"during":[10],"treatment":[11],"with":[12],"Teliso-V":[13,25],"monotherapy":[14],"Q2W":[15],"and":[16,19],"Q3W":[17],"cohorts":[18],"events":[22],"leading":[23],"to":[24],"dose":[26],"interruption/reduction":[27]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2024-11-04T00:00:00"}